First large-scale prospective evaluation of serum S100A6 as a complementary biomarker for early pancreatic cancer detection

Figure 2 Receiver operating characteristic curves for distinguishing pancreatic cancer from control groups. Areas under the curves with 95% confidence intervals are shown for the original dataset and internal validation, and areas under the curve comparisons were performed using DeLong’s test. EPC: Early pancreatic cancer; LPC: Late pancreatic cancer; H: Healthy control; CP: Chronic pancreatitis.